JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265254

Human ANKRD13A knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ANKRD13A KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human ANKRD13A knockout HeLa cell line (AB265254)
  • Sanger seq

Unknown

Sanger Sequencing - Human ANKRD13A knockout HeLa cell line (AB265254)

Homozygous : 7 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265254-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265254 Human ANKRD13A knockout HeLa cell line", "number":"AB265254-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265254-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265254-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265254-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265254 Human ANKRD13A knockout HeLa cell line", "number":"AB265254-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265254-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265254 Human ANKRD13A knockout HeLa cell line", "number":"AB265254-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265254-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265254 Human ANKRD13A knockout HeLa cell line", "number":"AB265254-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ANKRD13A
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ANKRD13A also known as Ankyrin Repeat Domain 13A is a protein weighing approximately 114 kDa. It contains ankyrin repeat motifs that facilitate protein-protein interactions making it important for cellular processes. ANKRD13A expresses widely across tissues with the highest levels in the brain heart and skeletal muscle. These repeat motifs are characteristic of proteins that participate in a variety of cellular functions suggesting ANKRD13A's role in maintaining cellular architecture and signaling.
Biological function summary

ANKRD13A interacts with several proteins implicating it in cellular adhesion and signaling pathways. It forms part of a complex involved in endocytosis and intracellular trafficking. These processes are essential for maintaining cellular communication and signaling balance. ANKRD13A's protein interactions suggest functions in regulating cell membrane dynamics and vesicle transport which are critical for constant cellular adaptation to environmental signals.

Pathways

ANKRD13A plays a significant role in endocytosis and neurotransmitter trafficking. It interacts within the endocytic pathway to regulate the internalization and sorting of membrane proteins. ANKRD13A has connections to clathrin-mediated endocytosis and may influence synaptic vesicle recycling. The protein associates with clathrin and adaptor protein complexes indicating its contribution to maintaining neurotransmitter homeostasis in neural pathways.

ANKRD13A has associations with neurological and cardiovascular conditions. Deregulation or mutations in ANKRD13A may contribute to neurodegenerative diseases such as Alzheimer's and heart diseases. The protein's link to dynamin and other cytoskeletal proteins is critical since these proteins play roles in amyloid precursor protein (APP) processing and endocytic pathways related to these illnesses. Understanding how ANKRD13A interacts in these contexts can help in exploring therapeutic options for these conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com